Skip to Main Content
It looks like you're using Internet Explorer 11 or older. This website works best with modern browsers such as the latest versions of Chrome, Firefox, Safari, and Edge. If you continue with this browser, you may see unexpected results.

The Faculty of Medicine - Immunology and Cancer Research: Berger Michael

Researchers

Last updated December 2021 -  Immunology and Cancer Research

List of Publications

(1) Maimon A, Levi-Yahid V, Ben-Meir K, Halpern A, Talmi Z, Priya S, et al. Myeloid cell–derived PROS1 inhibits tumor metastasis by regulating inflammatory and immune responses via IL-10. J Clin Invest 2021;131(10).

(2) Saragovi A, Abramovich I, Omar I, Arbib E, Toker O, Eyal G, et al. Systemic hypoxia inhibits T cell response by limiting mitobiogenesis via matrix substrate-level phosphorylation arrest. eLife 2020;9:1-50.

(3) Kolodny O, Berger M, Feldman MW, Ram Y. A new perspective for mitigation of SARS-CoV-2 infection: Priming the innate immune system for viral attack: Mitigation of SARS-CoV-2 infection. Open Biol 2020;10(7).

(4) Shamriz O, Simon AJ, Lev A, Megged O, Ledder O, Picard E, et al. Exogenous interleukin-2 can rescue in-vitro T cell activation and proliferation in patients with a novel capping protein regulator and myosin 1 linker 2 mutation. Clin Exp Immunol 2020;200(3):215-227.

(5) Lückel C, Picard F, Raifer H, Campos Carrascosa L, Guralnik A, Zhang Y, et al. IL-17+ CD8+ T cell suppression by dimethyl fumarate associates with clinical response in multiple sclerosis. Nat Commun 2019;10(1).

(6) Karsch-Bluman A, Feiglin A, Arbib E, Stern T, Shoval H, Schwob O, et al. Tissue necrosis and its role in cancer progression. Oncogene 2019;38(11):1920-1935.

(7) Malakar P, Stein I, Saragovi A, Winkler R, Stern-Ginossar N, Berger M, et al. Long noncoding RNA MALAT1 regulates cancer glucose metabolism by enhancing mTOR-Mediated Translation of TCF7L2. Cancer Res 2019;79(10):2480-2493.

(8) Omar I, Guterman-Ram G, Rahat D, Tabach Y, Berger M, Levaot N. Schlafen2 mutation in mice causes an osteopetrotic phenotype due to a decrease in the number of osteoclast progenitors. Sci Rep 2018;8(1).

(9) Yehuda Y, Blumenfeld B, Mayorek N, Makedonski K, Vardi O, Cohen-Daniel L, et al. Germline DNA replication timing shapes mammalian genome composition. Nucleic Acids Res 2018;46(16):8299-8310.

(10) Gamliel M, Goldman-Wohl D, Isaacson B, Gur C, Stein N, Yamin R, et al. Trained Memory of Human Uterine NK Cells Enhances Their Function in Subsequent Pregnancies. Immunity 2018;48(5):951-962.e5.

(11) Malka Y, Steiman-Shimony A, Rosenthal E, Argaman L, Cohen-Daniel L, Arbib E, et al. Post-transcriptional 3´-UTR cleavage of mRNA transcripts generates thousands of stable uncapped autonomous RNA fragments. Nat Commun 2017;8(1).

(12) Sun L, Jiang Z, Acosta-Rodriguez VA, Berger M, Du X, Choi JH, et al. HCFC2 is needed for IRF1- and IRF2-dependent Tlr3 transcription and for survival during viral infections. J Exp Med 2017;214(11):3263-3277.

(13) Omar I, Rom O, Aviram M, Cohen-Daniel L, Gebre AK, Parks JS, et al. Slfn2 mutation-induced loss of T-cell quiescence leads to elevated de novo sterol synthesis. Immunology 2017;152(3):484-493.

(14) Molho-Pessach V, Ramot Y, Mogilevsky M, Cohen-Daniel L, Eisenstein EM, Abu-Libdeh A, et al. Generalized verrucosis and abnormal T cell activation due to homozygous TAOK2 mutation. J Dermatol Sci 2017;87(2):123-129.

(15) Lapenna A, Omar I, Berger M. A novel spontaneous mutation in the tap2 gene unravels its role in macrophage survival. Immunology 2017;150(4):432-443.

(16) Morin MD, Wang Y, Jones BT, Su L, Surakattula MMRP, Berger M, et al. Discovery and Structure-Activity Relationships of the Neoseptins: A New Class of Toll-like Receptor-4 (TLR4) Agonists. J Med Chem 2016;59(10):4812-4830.

(17) Wang Y, Su L, Morin MD, Jones BT, Whitby LR, Surakattula MMRP, et al. Erratum: TLR4/MD-2 activation by a synthetic agonist with no similarity to LPS (Proceedings of the National Academy of Sciences of the United States of America (2016) 113 (E884-E893)). Proc Natl Acad Sci U S A 2016;113(14):E2096.

(18) Wang Y, Su L, Morin MD, Jones BT, Whitby LR, Surakattula MMRP, et al. TLR4/MD-2 activation by a synthetic agonist with no similarity to LPS. Proc Natl Acad Sci U S A 2016;113(7):E884-E893.

(19) Omar I, Lapenna A, Cohen-Daniel L, Tirosh B, Berger M. Schlafen2 mutation unravels a role for chronic ER stress in the loss of T cell quiescence. Oncotarget 2016;7(26):39396-39407.

(20) Goldshtein A, Zerbib SM, Omar I, Cohen-Daniel L, Popkin D, Berger M. Loss of T-cell quiescence by targeting Slfn2 prevents the development and progression of T-ALL. Oncotarget 2016;7(30):46835-46847.

(21) Finkin S, Yuan D, Stein I, Taniguchi K, Weber A, Unger K, et al. Ectopic lymphoid structures function as microniches for tumor progenitor cells in hepatocellular carcinoma. Nat Immunol 2015;16(12):1235-1244.

(22) Benhamron S, Pattanayak SP, Berger M, Tirosh B. mTOR activation promotes plasma cell differentiation and bypasses XBP-1 for immunoglobulin secretion. Mol Cell Biol 2015;35(1):153-166.

(23) Sabouri AH, Marcondes MCG, Flynn C, Berger M, Xiao N, Fox HS, et al. TLR signaling controls lethal encephalitis in WNV-infected brain. Brain Res 2014;1574:84-95.

(24) Goldshtein A, Berger M. Friend or foe: Can activating mutations in NOTCH1 contribute to a favorable treatment outcome in patients with T-ALL? Crit Rev Oncog 2014;19(5):399-404.

(25) Tardif V, Manenkova Y, Berger M, Hoebe K, Zuo J-, Yuan C, et al. Critical role of transmethylation in TLR signaling and systemic lupus erythematosus. Clin Immunol 2013;147(2):133-143.

(26) Arnold CN, Barnes MJ, Berger M, Blasius AL, Brandl K, Croker B, et al. ENU-induced phenovariance in mice: Inferences from 587 mutations. BMC Res Notes 2012;5.

(27) Berger M, Rosenschein JS. When to apply the fifth commandment: The effects of parenting on genetic and learning agents. J Exp Theor Artif Intell 2010;22(3):159-195.

(28) Berger M, Krebs P, Crozat K, Li X, Croker BA, Siggs OM, et al. An Slfn2 mutation causes lymphoid and myeloid immunodeficiency due to loss of immune cell quiescence. Nat Immunol 2010;11(4):335-343.

(29) Siggs OM, Berger M, Krebs P, Arnold CN, Eidenschenk C, Huber C, et al. A mutation of Ikbkg causes immune deficiency without impairing degradation of IκBα. Proc Natl Acad Sci U S A 2010;107(7):3046-3051.

(30) Louria-Hayon I, Alsheich-Bartok O, Levav-Cohen Y, Silberman I, Berger M, Grossman T, et al. E6AP promotes the degradation of the PML tumor suppressor. Cell Death Differ 2009;16(8):1156-1166.

(31) Croker BA, Lawson BR, Rutschmann S, Berger M, Eidenschenk C, Blasius AL, et al. Inflammation and autoimmunity caused by a SHP1 mutation depend on IL-1, MyD88, and a microbial trigger (Proceedings of the National Academy of Sciences of the United States of America (2008) 105, 39, (15028-15033) DOI:10.1073/pnas.0806619105). Proc Natl Acad Sci U S A 2008;105(49):19561.

(32) Croker BA, Lawson BR, Berger M, Eidenschenk C, Blasius AL, Moresco EMY, et al. Inflammation and autoimmunity caused by a SHP1 mutation depend on IL-1, MyD88, and a microbial trigger. Proc Natl Acad Sci U S A 2008;105(39):15028-15033.

(33) Croker B, Crozat K, Berger M, Xia Y, Sovath S, Schaffer L, et al. ATP-sensitive potassium channels mediate survival during infection in mammals and insects. Nat Genet 2007;39(12):1453-1460.

(34) Berger M, Stahl N, Del Sal G, Haupt Y. Mutations in proline 82 of p53 impair its activation by Pin1 and Chk2 in response to DNA damage. Mol Cell Biol 2005;25(13):5380-5388.

(35) When to apply the fifth commandment: The effects of parenting on genetic and learning agents. Proceedings of the Third International Joint Conference on Autonomous Agents and Multiagent Systems, AAMAS 2004; 2004.

(36) Haupt S, Berger M, Goldberg Z, Haupt Y. Apoptosis - The p53 network. J Cell Sci 2003;116(20):4077-4085.

(37) Berger M, Haupt Y. Flow cytometric analysis of p53-induced apoptosis. Methods Mol Biol 2003;234:245-256.

(38) Goldberg Z, Sionov RV, Berger M, Zwang Y, Perets R, Van Etten RA, et al. Tyrosine phosphorylation of Mdm2 by c-Abl: Implications for p53 regulation. EMBO J 2002;21(14):3715-3727.

(39) Vogt Sionov R, Coen S, Goldberg Z, Berger M, Bercovich B, Ben-Neriah Y, et al. c-Abl regulates p53 levels under normal and stress conditions by preventing its nuclear export and ubiquitination. Mol Cell Biol 2001;21(17):5869-5878.

(40) Berger M, Sionov RV, Levine AJ, Haupt Y. A Role for the Polyproline Domain of p53 in Its Regulation by Mdm2. J Biol Chem 2001;276(6):3785-3790.

(41) Müller S, Berger M, Lehembre F, Seeler J-, Haupt Y, Dejean A. c-Jun and p53 activity is modulated by SUMO-1 modification. J Biol Chem 2000;275(18):13321-13329.

(42) Unger T, Juven-Gershon T, Moallem E, Berger M, Vogt Sionov R, Lozano G, et al. Critical role for Ser20 of human p53 in the negative regulation of p53 by Mdm2. EMBO J 1999;18(7):1805-1814.

(43) Sionov RV, Moallem E, Berger M, Kazaz A, Gerlitz O, Ben-Neriah Y, et al. c-Abl neutralizes the inhibitory effect of Mdm2 on p53. J Biol Chem 1999;274(13):8371-8374.